BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

NCT06205706 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Non Small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions

DRUG: BI-1910
DRUG: Pembrolizumab

Sponsor

BioInvent International AB

Collaborators

[object Object]